Diltiazem Hydrochloride
Total Payments
$1.1M
Transactions
10
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2021 | $1.1M | 10 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.1M | 10 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| DILT-CAR-1001 | Mylan Pharmaceuticals Inc. | $614,145 | 0 |
| DILT-1-19086 | Mylan Pharmaceuticals Inc. | $436,911 | 0 |
Top Doctors Receiving Payments for Diltiazem Hydrochloride
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Miami, FL | $1.1M | 10 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $1.1M
- Total Doctors 0
- Transactions 10
About Diltiazem Hydrochloride
Diltiazem Hydrochloride is a drug associated with $1.1M in payments to 0 healthcare providers, recorded across 10 transactions in the CMS Open Payments database. The primary manufacturer is Mylan Pharmaceuticals Inc..
Payment data is available from 2021 to 2021. In 2021, $1.1M was paid across 10 transactions to 0 doctors.
The most common payment nature for Diltiazem Hydrochloride is "Unspecified" ($1.1M, 100.0% of total).
Diltiazem Hydrochloride is associated with 2 research studies, including "DILT-CAR-1001" ($614,145).